Multi-omics identifies PCK1-associated immunometabolic regulation underlying the protective effects of sinomenine in vascular dementia.
Findings suggest that SIN alleviates VaD-associated microglial dysfunction by modulating PCK1-associated immunometabolic alterations, and expands the current understanding of the pharmacological actions of SIN.